Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 140

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 2
Chunk 140
---
 2024Biotechnology$1,850 $1,713 $3,462 $3,237 Life Sciences1,777 1,770 3,457 3,515 Diagnostics2,309 2,260 4,758 4,787 Total$5,936 $5,743 $11,677 $11,539 

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.

BIOTECHNOLOGY

The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

28

Biotechnology Selected Financial Data 

 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$1,850 $1,713 $3,462 $3,237 Operating profit531 462 972 787 Depreciation38 35 72 77 Amortization of intangible assets228 214 441 432 Operating profit as a % of sales28.7 %27.0 %28.1 %24.3 %Depreciation as a % of sales2.1 %2.0 %2.1 %2.4 %Amortization as a % of sales12.3 %12.5 %12.7 %13.3 %

Sales Growth and Core Sales Growth% Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period% Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)8.0 %7.0 %Impact of:Currency exchange rates (2.0)%(0.5)%Core sales growth (non-GAAP)6.0 %6.5 %

Price increases in the segment contributed 2.5